DiagnosticReport_Srvlt

Medical Testing Laboratory - Yashoda Hospital & Research Centre Page 1 of 1
Patient Name : Mr. Bhawani Mishra Reg No. : 42764/OPDPB24HO Lab No. : 42764/OPDPB24HO
Age / Gender : 65Y / Male Date : 24-Jun-2024
Refd. By : ECHS Specimen : SERUM
Collectedt : 24-Jun-2024 09.41
Uhid No. : 43142/UHID22HO :
Manual No. 816 Received : 24-Jun-2024 09.50
Sample Id : 2498313 Report YH-Nehru Nagar : 24-Jun-2024 11.14 MC-3022
TEST NAME RESULT UNIT RANGE LEVEL
BIOCHEMISTRY
KIDNEY FUNCTION TEST
BLOOD GLUCOSE ,Serum 316.0 mg/dl 70-140 High
hexokinase
BLOOD UREA,SERUM 47 mg/dl 10-50 WNL
(Uricase)
CREATININE, SERUM 0.94 mg/dl 0.72-1.25 WNL
(ALKALINE PICRATE KINETIC)
URIC ACID, SERUM 2.70 mg/dl 3.0-7.0 Low
(URICASE)
TOTAL PROTEIN, SERUM 6.90 g/dl 6.7-8.7 WNL
(BIURET REAGENT BLANK)
ALBUMIN, SERUM 4.20 g/dl 3.5-5.0 WNL
(BCG)
GLOBULIN, Serum 2.70 g/dl 2 - 3.5 WNL
(BCG Method)
SODIUM, SERUM 134 mmol/L 135-145 Low
(ISE DIRECT)
POTASSIUM, SERUM 4.40 mmol/L 3.5-5.2 WNL
(ISE DIRECT)
CALCIUM, SERUM 9.80 mg/dl 8.1-10.5 WNL
(ARSENA20III)
PHOSPHORUS, SERUM 3.10 mg/dl 2.5-4.5 WNL
(PHOSPHOMOLYBABATE REDUCTION)
CHOLESTEROL, SERUM 128.00 mg/dl 130-200 Low
(Cholesterol Oxidase Esterase Peroxidase)
CHLORIDE, SERUM 104.00 mmol/L 98.0-115 WNL
(ISE DIRECT)
-----------------End of Report-----------------
Dr. BRIG. AJAY MALIK Dr. SHUCHI GHAI Dr. TANVI ARORA Dr. SHREYA CHAUDHURI
CHIEF PATHOLOGIST CONSULTANT CONSULTANT CONSULTANT
PATHOLOGIST PATHOLOGIST MICROBIOLOGIST
Prepared By : madhav
Refd. By : ECHS Specimen : BLOOD
Sample Id : 2498313 Report YH-Nehru Nagar : 24-Jun-2024 11.14
BIOCHEMISTRY
LIPID PROFILE, SERUM
CHOLESTEROL, SERUM 128.00 mg/dl 130-200 Low
(Cholesterol Oxidase Esterase Peroxidase)
TRIGLYCERIDES, SERUM 90.00 mg/dl 40 - 160 WNL
(GPO -PAP Method)
Suggested risk levels for CAD
Levels (mg/dl) Interpretation
< 160 Normal
160 - 199 Borderline high
200 - 499 High
> 500 Very high
Comments :
Elevated levels can be seen with
·Overnight fasting less than 12 hrs.
·Non insulin dependent Diabetes mellitus
·Hepatitis
·Intrahepatic biliary obstruction
·Cirrhosis
·Obesity
·Alcohol intake
·Pancreatitis (level > 500mg/dl)
·Drug use
Thiazide
Cholestyramine
Corticosteroids
HDL-CHOL, SERUM 49.00 mg/dl 35 - 60 WNL

(Immunoinhibition Method)
Comments :
·This test is used to asses risk for CAD and in diagnosis of
various lipo proteinemia.
·For every 1mg/dl decrease in HDL risk for CAD increase by 2-
3%.
·Decreased levels are seen in
-Diabetes mellitus
-Obesity
-Stress
-Starvation
-Smoking
-Hypothyroidism
-Drug use (anabolic steroids, b blockers, thiazide
LDL-CHOL, SERUM 73.00 mg/dl < 130 WNL
(Measured, Liquid Selective Detergent)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Suggested risk for CAD

Levels Interpretation
< 130 Desirable
130 - 159 Borderline risk
> 160 high risk
Comments :
-This test is used to asses risk, monitor and decide
treatment & CAD
-Increased levels are seen in
· Familial hypercholesterolemia
· Diabetes mellitus
· Hypothyroidism
· Nephrotic syndrome
· CRF
· Multiple myelome.
VLDL 18 mg/dl <40 WNL

TOTAL LIPID 267 mg/dl 400-700 Low
TOTAL CHOLESTROL : HDL RATIO 2.61 3.43 - 4.4 Low
-----------------End of Report-----------------
Refd. By : ECHS Specimen : SERUM
BIOCHEMISTRY
LIVER FUNCTION TEST
SGOT, SERUM(AST) 23.00 IU/L 0-46 WNL
NADH(Without P-5-P)
SGPT, SERUM(ALT) 20.00 IU/L 0-49 WNL
NADH(Without P-5-P)
ALKALINE PHOSPHATASE, SERUM 154 IU/L 40-150 High
(PNPPAMP BUFFER)
TOTAL PROTEIN, SERUM 6.90 g/dl 6.7-8.7 WNL
(BIURET REAGENT BLANK)
ALBUMIN, SERUM 4.20 g/dl 3.5-5.0 WNL
(BCG)
GLOBULIN, Serum 2.70 g/dl 2 - 3.5 WNL
(BCG Method)
GAMA GT, SERUM 20.00 IU/L 4-25 WNL
(G-3,C-4,NITROANILIDE SUBSTRATE)
BILIRUBIN TOTAL DIRECT, SERUM
TOTAL 1.31 mg/dl 0.2 - 1.2 High
(Diazonium salt)
DIRECT 0.39 mg/dl 0<0.5 WNL
(Diazotization salt)
INDIRECT 0.92 mg/dl
(Calculated)
-----------------End of Report-----------------
Refd. By : ECHS Specimen : WHOLE BLOOD EDTA
HAEMATOLOGY
COMP.HAEMOGRAM(CBC)
HAEMOGLOBIN 12.00 g/dl 13.0 - 17.0 Low
(Spectrophotometry)
TOTAL LEUCOCYTE COUNT (TLC) 4.06 X10^3/mm3 4.0 - 10.0 WNL
(Impedence Method)
PLATELET COUNT 150.00 X10^3/mm3 150 - 410 WNL
(Impedence Method)
HEMATOCRIT (HCT) 37.9 dl/dl 40.0 - 50.0 Low
(Numeric Intregration)
RBC COUNT 4.49 x10^12/µl 4.50 - 5.00 Low
(Impedence Method)
MCV 85 fL 83.0 - 101.0 WNL
(Numeric integration)
MCH 26.70 pg 27.0 - 32.0 Low
(Calculated)
MCHC 31.60 g/dl 31.5 - 34.5 WNL
(Calculated)
RED DISTRIBUTION WIDTH (RDW) 15.5 % 11.5 - 14.5 High
(Calculated)
MPV 12.3 fL 7.2-11.1 High
(Calculated)
DLC (DIFFERENTIAL LEUCOCYTE COUNT)
SEGMENTED NEUTROPHILS 50.5 % 40.0 - 80.0 WNL
(Flow cytometry / Light Microscopy)
LYMPHOCYTES 36.3 % 20.0 - 40.0 WNL
MONOCYTES 9.3 % 2.0 - 10.0 WNL
EOSINOPHILS 3.2 % 1.0 - 6.0 WNL
BASOPHILS 0.4 % <1.0 - 2.0 WNL
Prepared By : ASHISH
Refd. By : ECHS Specimen : WHOLE BLOOD EDTA
#ATYPICAL LYMPHOCYTES 2.2 % 0.5 - 2.8 WNL

#LARGE IMMATURE CELLS 0.3 % 0.2-1.4 WNL
ABSOLUTE COUNT
SEGMENTED NEUTROPHILS 2.0 X10^3/mm3 2.0 - 7.0 WNL
LYMPHOCYTES 1.48 X10^3/mm3 1.00 - 3.00 WNL
MONOCYTES 0.38 X10^3/mm3 0.20 - 1.00 WNL
EOSINOPHILS 0.13 X10^3/mm3 0.02 - 0.50 WNL
BASOPHILS 0.02 X10^3/mm3 0.02 - 0.1 WNL
#ATYPICAL LYMPHOCYTES 0.09 X10^3/mm3 0.02 - 0.5 WNL
#LARGE IMMATURE CELLS 0.01 X10^3/mm3 0.02 - 0.5 Low
-----------------End of Report-----------------
Prepared By : ASHISH
HAEMATOLOGY
GLYCOSYLATED HAEMOGLOBIN ..
(HbA1C)
HbA1c (GLYCOSYLATED HEMOGLOBIN 12.0 % See below
(HPLC)
eAG CALCULATED 297.7 mg/dL < 140.0
ADA is recommending estimated average glucose, or eAG for diabetes mellitus management. The eAG is a value calculated from HbA1c and
represents an average of glucose levels over the previous three month period.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Interpretation
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| As per American Diabetes Association (ADA) |
----------------------------------------------------------------------------------------
| Refrence Group | HbA1c in % |
----------------------------------------------------------------------------------------
| Non Diabetic adults > =18 years | 4.0 - 6.0 |
-----------------------------------------------------------------------------------------
| At Risk | > = 6.0 to < = 6.5 |
-----------------------------------------------------------------------------------------
| Diagnosting Diabetes | > 6.5 |
-----------------------------------------------------------------------------------------
| Therapeutic goals for glycemic | Age > 19 Years |
| control | *Goal of therapy : < 7.0 |
| | *Action suggested : > 8.0 |
| | |
| | Age < 19 Years |
| | * Goal of therapy : < 7.5 |
----------------------------------------------------------------------------------------
Note:
1.Since HbA1c reflects long term fluctuations in the blood glucose concentration, diabetic patient who is recntly under good control
may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
2. Target goals of <7.0 % may be benificial in patients with short duration of diabetes, long life expectancy and no sgnificant
cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid
conditions,targeting a goal of <7.0 % may not be appropriate.
Comments:
HbA1c provides an index of average blood glucose levels over past 8 -12 weeks and is a much better indicator of long term glycemic control as
compared to blood and urinary glucose determination.
ADA criteria for correlation between HbA1c & mean plasma glucose levels
---------------------------------------------------------------------------------------
Prepared By : AN
| HbA1c (%) | Mean Plasma Glucose (mg/dL) |

---------------------------------------------------------------------------------------
| 6 | 126 |
---------------------------------------------------------------------------------------
| 7 | 154 |
----------------------------------------------------------------------------------------
| 8 | 183 |
------------------------------------------------------------------ ---------------------
| 9 | 212 |
---------------------------------------------------------------------------------------
| 10 | 240 |
---------------------------------------------------------------------------------------
| 11 | 269 |
----------------------------------------------------------------------------------------
| 12 | 298 |
----------------------------------------------------------------------------------------
-----------------End of Report-----------------
Prepared By : AN
IMMUNOLOGY
TSH ULTRASENSITIVE 0.6160 ulU/ml 0.35 - 4.94 WNL
Method: CMIA
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
CHILDREN
PRE MATURE-28-36 WEEKS : 0.7 - 27
BIRTH-4 DAYS : 1.0 - 39
5 DAYS - 5 MONTHS : 1.7 - 9.1
5 MONTHS - 20 YEARS : 0.7 - 6.4
ADULTS : 0.35 - 4.94
PREGNANCY
Ist Trimester : 0.10 - 2.50
IInd Trimester : 0.20 - 3.00
IIIrd Trimester : 0.30 - 3.00
Note: TSH levels are subject to circadian variation, reaching peak between 2 - 4am and minimum between 6 - 10pm. The variation is of the order
of 50%, hence time of the day has influence on the measured serum TSH concentration.
Clinical use:
Diagnose hypothyroidism and hyperthyroidism.
Monitor T4 replacement or T4 suppressive therapy.
Quantify TSH levels in the subnormal range.
Increased levels:
Primary hypothyroidism
Subclinical hypothyroidism
TSH dependent Hyperthyroidism
Decreased levels:
Graves disease
Autonomous thyroid hormone secretion
TSH deficiency
-----------------End of Report-----------------

DiagnosticReport_Srvlt

Uploaded by

Copyright:

Available Formats

You might also like

DiagnosticReport_Srvlt

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

DiagnosticReport_Srvlt

Uploaded by

Copyright:

Available Formats

Medical Testing Laboratory - Yashoda Hospital & Research Centre Page 1 of 1

TEST NAME RESULT UNIT RANGE LEVEL

TEST NAME RESULT UNIT RANGE LEVEL

HDL-CHOL, SERUM 49.00 mg/dl 35 - 60 WNL

TEST NAME RESULT UNIT RANGE LEVEL

Suggested risk for CAD

VLDL 18 mg/dl <40 WNL

TOTAL CHOLESTROL : HDL RATIO 2.61 3.43 - 4.4 Low

TEST NAME RESULT UNIT RANGE LEVEL

TEST NAME RESULT UNIT RANGE LEVEL

TEST NAME RESULT UNIT RANGE LEVEL

#ATYPICAL LYMPHOCYTES 2.2 % 0.5 - 2.8 WNL

TEST NAME RESULT UNIT RANGE LEVEL

TEST NAME RESULT UNIT RANGE LEVEL

| HbA1c (%) | Mean Plasma Glucose (mg/dL) |

TEST NAME RESULT UNIT RANGE LEVEL

You might also like